The Journal of Allergy and Clinical Immunology: In Practice

Slides:

Advertisements

Similar presentations

WAO Global Hereditary Angioedema (HAE) Practice Parameter

Advertisements

Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási,

Complementary and Alternative Medicine Use among Allergy Practices: Results of a Nationwide Survey of Allergists Michael H. Land, MD, Julie Wang, MD

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients Henriette Farkas, MD, PhD, DSc, Dorottya.

Erika Kajdácsi, MSc, Péter K

Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1- Inhibitor Deficiency Andrea Zanichelli, MD, Giulia Maria Azin, MD, Maddalena.

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy,

Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema William R. Lumry, MD, Timothy Craig,

Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data Marc A. Riedl, MD, MS, Anette Bygum, MD, William Lumry, MD, Markus Magerl,

Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives Iris M. Otani, MD, Sandra C. Christiansen, MD, Paula Busse, MD,

Aleena Banerji, MD, Kimberly G. Blumenthal, MD, MSc, Kenneth H

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy,

Primary Prevention of Food Allergy: Translating Evidence from Clinical Trials to Population-Based Recommendations Paul J. Turner, FRACP, PhD, Dianne.

Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Activation of the ficolin-lectin pathway during attacks of hereditary angioedema Dorottya Csuka, PhD, Lea Munthe-Fog, PhD, Estrid Hein, MSc, Zsuzsanna.

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients Henriette Farkas, MD, PhD, DSc, Dorottya.

Erika Kajdácsi, MSc, Péter K

Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema Tom Bowen, MD, FRCPC, Marco Cicardi,

Recurrent anaphylaxis linked to pantoprazole

Short-term prophylaxis in a patient with acquired C1-INH deficiency

Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and Course Konrad Bork, MD, Gabriele Meng, MD, Petra Staubach, MD, Jochen Hardt,

Suspecting and Testing for Alpha-1 Antitrypsin Deficiency—An Allergist's and/or Immunologist's Perspective Timothy J. Craig, DO The Journal of Allergy.

Recurrent Retroperitoneal Angioedema

Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone.

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review Amy S. Levin, MD, Iris M. Otani, MD, Timothy Lax, MD, Ephraim Hochberg, MD, Aleena.

Practice Notes from the AAAAI

Timothy J. Craig, DO, H. Henry Li, MD, Marc Riedl, MD, Jonathan A

A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema

Nonadherence to Asthma Treatment: Getting Unstuck

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet Hendrik Nolte, MD, PhD, David I. Bernstein,

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients.

Successful treatment of idiopathic angioedema with ecallantide

Elena Almarza Novoa, PhD, Sanchali Kasbekar, PharmD, Adrian J

Thys van der Molen, MD, PhD, Monica Fletcher, MSc, David Price, FRCGP

Reply The Journal of Allergy and Clinical Immunology: In Practice

Value of a Second Dose of Epinephrine During Anaphylaxis: A Patient/Caregiver Survey T. Ted Song, DO, Duncan Brown, PhD, Martin Karjalainen, MD, Ulrike.

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Change in Asthma Control Over Time: Predictors and Outcomes

Phillip Lieberman, MD, Michael Tankersley, MD

The Emperor Has No Symptoms: The Risks of a Blanket Approach to Using Epinephrine Autoinjectors for All Allergic Reactions Paul J. Turner, FRACP, PhD,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

The Management of Eosinophilic Esophagitis

Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated

Anaphylactic Reaction to White-Faced Hornet Sting and Elevated Baseline (Asymptomatic) Serum Tryptase Phillip Lieberman, MD, Lawrence B. Schwartz, MD,

Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási,

Andy Kusuma, MD, Anurag Relan, MD, André C

Reply Journal of Allergy and Clinical Immunology

Sharon Seth, MD, David A. Khan, MD

Jeffrey M. Harris, MD, PhD, Christopher R

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH- HAE: SAHARA Randomized Study William R. Lumry, MD, Inmaculada Martinez-Saguer,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet Hendrik Nolte, MD, PhD, David I. Bernstein,

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind,

Reply The Journal of Allergy and Clinical Immunology: In Practice

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency Marcel Levi, MD,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously Shilpa H. Desai, BS, MD, Akhil Chouksey, MD, John Poll, RN, Melvin Berger,

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

Primary Prevention of Food Allergy: Translating Evidence from Clinical Trials to Population-Based Recommendations Paul J. Turner, FRACP, PhD, Dianne.

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Presentation transcript:

The Journal of Allergy and Clinical Immunology: In Practice Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks Timothy Craig, DO, Bruce Zuraw, MD, Hilary Longhurst, MD, Marco Cicardi, MD, Konrad Bork, MD, Clive Grattan, MD, Constance Katelaris, MD, Gordon Sussman, MD, Paul K. Keith, MD, William Yang, MD, Jacques Hébert, MD, Jana Hanzlikova, MD, Petra Staubach-Renz, MD, Inmaculada Martinez-Saguer, MD, Markus Magerl, MD, Emel Aygören-Pürsün, MD, Henriette Farkas, MD, PhD, DSc, Avner Reshef, MD, Shmuel Kivity, MD, Sergio Neri, MD, Ioana Crisan, MD, Teresa Caballero, MD, PhD, Maria L. Baeza, MD, PhD, Maria Dolores Hernandez, MD, Henry Li, MD, William Lumry, MD, Jonathan A. Bernstein, MD, Iftikar Hussain, MD, John Anderson, MD, Lawrence B. Schwartz, MD, Joshua Jacobs, MD, Michael Manning, MD, Donald Levy, MD, Marc Riedl, MD, Sandra Christiansen, MD, Henrike Feuersenger, PhD, Ingo Pragst, PhD, Sarah Mycroft, MD, Dipti Pawaskar, PhD, Iris Jacobs, MD The Journal of Allergy and Clinical Immunology: In Practice DOI: 10.1016/j.jaip.2019.01.054 Copyright © 2019 The Authors Terms and Conditions

Figure 1 Trial profile. Patient disposition for the trial and extension periods. Arrows indicate uptitration of dose. AE, Adverse event; MI, myocardial infarction; TP1, trial period 1; TP2, trial period 2; IU, international units. The Journal of Allergy and Clinical Immunology: In Practice DOI: (10.1016/j.jaip.2019.01.054) Copyright © 2019 The Authors Terms and Conditions

Figure 2 Percentage of patients with more than 2 years' exposure who were attack-free by 6-month time window (A) and who did not use any rescue medication (B), by 6-month time window. IU, International units. The Journal of Allergy and Clinical Immunology: In Practice DOI: (10.1016/j.jaip.2019.01.054) Copyright © 2019 The Authors Terms and Conditions

Figure 3 Pharmacokinetic and pharmacodynamic findings over the course of the study. Mean (dots) and SD (vertical lines) of C1-INH functional activity (A), C1-INH protein (B), and C4 protein (C). The gray boxed area indicates the extended study period. LLN, Lower limit of normal (LLN taken from Tarzi et al15). IU, International units. The Journal of Allergy and Clinical Immunology: In Practice DOI: (10.1016/j.jaip.2019.01.054) Copyright © 2019 The Authors Terms and Conditions